C-Bridge Capital, a Shanghai-based private equity firm focused on China’s healthcare sector, hopes to profit handsomely by bringing better drug know-how from developed markets to the underdeveloped Chinese pharmaceutical industry. Headed by finance veteran Fu Wei, the US$700 million-under-management firm led a follow-on US$100 million round in Chinese pharmaceutical start-up Ascletis earlier this month. Ascletis has licensed and conducted clinical trail on a hepatitis C treatment drug developed by an American company, and is launching the drug in China during the …
C-Bridge’s Fu Wei Aims To Profit By Transferring Pharma Tech To China appeared first on China Money Network.